Ampersand Biomedicines

News

Recent financings in the biotech space include rounds for Character Bio, Tempero, Epicrispr, Hillstar Bio, and Ampersand Biomedicines.

News

MSD's TROP2-targeting antibody-drug conjugate sac-TMT, licensed from China's Kelun, has improved survival in a late-stage endometrial cancer trial.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.